


Richcore LifeSciences expands manufacturing capability

22 July 2020 | News

Richcore's expansion will go a long way in augmenting indigenous manufacturing of biomedical resources and strengthening India's domestic supply chain



Bengaluru based biotech company, Richcore Life Sciences is expanding its manufacturing capability by building a second recombinant protein manufacturing facility, R2 at Vasanthanarasapura,Tumkur a tier two city in Karnataka.

The facility will house a state-of-the-art 180 thousand Litre fermentation capability which can produce multiple recombinant biotechnology products for Biopharma, Cell culture and Food industries.

This new facility will help Richcore multiply its manufacturing capability 20 times by January 2021 and is the first of the many large scale global quality Bio-Manufacturing sites Richcore plans to establish in the next few years.

The foundation stone for the Tumakuru facility was laid by the Deputy Chief Minister of Karnataka and IT / BT, Sicence & Technology Minister, Dr C.N Ashwathnarayan on June 15th 2020.

While congratulating the Richcore team, he said, that it is "Great to see Karnataka's BT sector continue expanding beyond the city limits of Bengaluru into innovative tier two cities" and appreciated Richcore's "Make in India" Initiative.

Richcore's expansion will go a long way in augmenting indigenous manufacturing of biomedical resources and strengthening India's domestic supply chain, especially important in the backdrop of the Government's call for local sourcing and local manufacturing.

Established in 2005 and currently located in Jigani, Bengaluru, Richcore's USP is Non-Animal Origin 'green' recombinant protein technology. Their products enable global biologics, vaccine and cell culture companies, achieve higher levels of drug safety compliance by replacing viral-contamination prone, animal-derived components with their recombinant Non-animal Origin (NAO) alternatives. For example, their recombinant trypsin (rcTrypsin) has enabled production of more than 10 billion doses of safer insulin shots till date. Moreover optimized cGMP development & cGMP certified manufacturing platforms enable them to adhere to international quality control and safety standards.